Back to Journals » International Journal of Nanomedicine » Volume 11

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Authors Li M, Zhang W, Wang B, Gao Y, Song Z, Zheng QC

Received 24 June 2016

Accepted for publication 19 September 2016

Published 31 October 2016 Volume 2016:11 Pages 5645—5669

DOI https://doi.org/10.2147/IJN.S115727

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Alexander Kharlamov

Peer reviewer comments 3

Editor who approved publication: Dr Linlin Sun


Min Li,1 Weiyue Zhang,2 Birong Wang,3 Yang Gao,1 Zifang Song,1 Qi Chang Zheng1

1Department of Hepatobiliary Surgery, Union Hospital, 2The First Clinic Institute, Tongji Medical College, Huazhong University of Science and Technology, 3Department of Breast and Thyroid Surgery, Puai Hospital, Wuhan, The People’s Republic of China

Abstract: Hepatocellular carcinoma (HCC) is the most common primary liver cancer with high morbidity and mortality worldwide. Chemotherapy is recommended to patients with intermediate or advanced stage cancer. However, the conventional chemotherapy yields low desired response rates due to multidrug resistance, fast clearance rate, nonspecific delivery, severe side effects, low drug concentration in cancer cells, and so on. Nanoparticle-mediated targeted drug delivery system can surmount the aforementioned obstacles through enhanced permeability and retention effect and active targeting as a novel approach of therapeutics for HCC in recent years. The active targeting is triggered by ligands on the delivery system, which recognize with and internalize into hepatoma cells with high specificity and efficiency. This review focuses on the latest targeted delivery systems for HCC and summarizes the ligands that can enhance the capacity of active targeting, to provide some insight into future research in nanomedicine for HCC.

Keywords: targeted therapy, hepatocellular carcinoma, ligand, drug delivery system, nanoparticle

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]